Genfit S.A. (NASDAQ:GNFT) Short Interest Update

Genfit S.A. (NASDAQ:GNFT - Get Free Report) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 98,900 shares, an increase of 15.1% from the February 29th total of 85,900 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 18,700 shares, the days-to-cover ratio is currently 5.3 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Genfit in a research note on Friday, December 8th.

Genfit Trading Up 0.3 %

Shares of GNFT stock traded up $0.01 during mid-day trading on Tuesday, hitting $3.57. 4,758 shares of the stock were exchanged, compared to its average volume of 17,420. The firm has a fifty day moving average of $3.69 and a 200 day moving average of $3.50. Genfit has a 52-week low of $2.89 and a 52-week high of $4.75.

Institutional Investors Weigh In On Genfit

Several hedge funds have recently modified their holdings of the company. O Shaughnessy Asset Management LLC raised its position in shares of Genfit by 32.5% during the 2nd quarter. O Shaughnessy Asset Management LLC now owns 32,423 shares of the company's stock worth $115,000 after purchasing an additional 7,961 shares during the last quarter. Citadel Advisors LLC raised its position in shares of Genfit by 181.8% during the 3rd quarter. Citadel Advisors LLC now owns 35,319 shares of the company's stock worth $129,000 after purchasing an additional 22,786 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Genfit by 39.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 26,554 shares of the company's stock worth $116,000 after purchasing an additional 7,455 shares during the last quarter. OLD Mission Capital LLC acquired a new position in shares of Genfit during the 4th quarter worth about $48,000. Finally, BNP Paribas Arbitrage SNC raised its position in shares of Genfit by 1,992.8% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 11,845 shares of the company's stock worth $43,000 after purchasing an additional 11,279 shares during the last quarter. 2.24% of the stock is owned by hedge funds and other institutional investors.

About Genfit

Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia.